MedPath

Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Phase 1
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Biological: EGFRt/BCMA-41BBz CAR T cell
Drug: Cyclophosphamide
Drug: Lenalidomide.
First Posted Date
2017-03-03
Last Posted Date
2024-03-04
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
20
Registration Number
NCT03070327
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Phase 1
Active, not recruiting
Conditions
Metastatic Malignant Neoplasm in the Liver
Metastatic Uveal Melanoma
Interventions
Biological: Aldesleukin
Biological: Autologous CD8+ SLC45A2-specific T Lymphocytes
Drug: Cyclophosphamide
Biological: Ipilimumab
First Posted Date
2017-03-03
Last Posted Date
2024-01-25
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
34
Registration Number
NCT03068624
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Phase 1
Completed
Conditions
Breastcancer
Breast Neoplasm
Interventions
Biological: SV-BR-1-GM
Drug: Cyclophosphamide
Biological: Interferon-alpha-2b
First Posted Date
2017-03-01
Last Posted Date
2021-01-29
Lead Sponsor
BriaCell Therapeutics Corporation
Target Recruit Count
24
Registration Number
NCT03066947
Locations
🇺🇸

St. Joseph Heritage Healthcare, Santa Rosa, California, United States

🇺🇸

University of Miami/Sylvester at Plantation, Plantation, Florida, United States

🇺🇸

Cancer Center of Kansas (CCK), Wichita, Kansas, United States

and more 2 locations

Clinical Trial Evaluating Metronomic Chemotherapy in Patients With Metastatic Osteosarcoma

Phase 2
Conditions
Osteosarcoma
Interventions
First Posted Date
2017-02-24
Last Posted Date
2017-03-13
Lead Sponsor
Grupo de Apoio ao Adolescente e a Crianca com Cancer
Target Recruit Count
158
Registration Number
NCT03063983
Locations
🇧🇷

Grupo de Apoio ao Adolescente e a Criança com Câncer, Sao Paulo, Brazil

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

Phase 2
Conditions
High Risk Neuroblastoma
Interventions
First Posted Date
2017-02-23
Last Posted Date
2018-09-18
Lead Sponsor
Samsung Medical Center
Target Recruit Count
40
Registration Number
NCT03061656

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Phase 1
Completed
Conditions
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-hodgkin Lymphoma
B-Lymphoid Malignancies
Interventions
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mesna
Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells
Drug: AP1903
First Posted Date
2017-02-17
Last Posted Date
2024-03-25
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
49
Registration Number
NCT03056339
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Phase 1
Completed
Conditions
Lymphoma, Extranodal NK-T-Cell
Enteropathy-Associated T-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, T-Cell, Peripheral
Lymphoma, Large-Cell, Anaplastic
Interventions
Biological: Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2017-02-10
Last Posted Date
2023-01-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
26
Registration Number
NCT03049449
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

Phase 1
Conditions
Stage IV Gastric Carcinoma
Stage IV Nasopharyngeal Carcinoma
T-Cell Lymphoma Stage IV
Stage IV Adult Hodgkin Lymphoma
Stage IV Diffuse Large B-Cell Lymphoma
Interventions
First Posted Date
2017-02-07
Last Posted Date
2017-05-02
Lead Sponsor
Yang Yang
Target Recruit Count
20
Registration Number
NCT03044743
Locations
🇨🇳

The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial

Phase 2
Conditions
Multicentric Castleman Disease
Interventions
First Posted Date
2017-02-03
Last Posted Date
2020-04-16
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
25
Registration Number
NCT03043105
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Phase 1
Completed
Conditions
Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma
Interventions
First Posted Date
2017-01-30
Last Posted Date
2022-08-24
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
31
Registration Number
NCT03036904
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath